BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15880659)

  • 1. Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ.
    Numa MM; Lee LV; Hsu CC; Bower KE; Wong CH
    Chembiochem; 2005 Jun; 6(6):1002-6. PubMed ID: 15880659
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
    Lee LV; Bower KE; Liang FS; Shi J; Wu D; Sucheck SJ; Vogt PK; Wong CH
    J Am Chem Soc; 2004 Apr; 126(15):4774-5. PubMed ID: 15080670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.
    Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
    J Med Chem; 2006 Aug; 49(17):5232-44. PubMed ID: 16913712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stop the killer: how to inhibit the anthrax lethal factor metalloprotease.
    Montecucco C; Tonello F; Zanotti G
    Trends Biochem Sci; 2004 Jun; 29(6):282-5. PubMed ID: 15276179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor.
    Hanna ML; Tarasow TM; Perkins J
    Bioorg Chem; 2007 Feb; 35(1):50-8. PubMed ID: 16949126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.
    Jiao GS; Simo O; Nagata M; O'Malley S; Hemscheidt T; Cregar L; Millis SZ; Goldman ME; Tang C
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5183-9. PubMed ID: 16870442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of anthrax lethal factor.
    Gaddis BD; Avramova LV; Chmielewski J
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4575-8. PubMed ID: 17574849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.
    Gaddis BD; Rubert PĂ©rez CM; Chmielewski J
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2467-70. PubMed ID: 18314330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.
    Jiao GS; Cregar L; Goldman ME; Millis SZ; Tang C
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1527-31. PubMed ID: 16386899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and binding-mode prediction of thiopyrone-based inhibitors of anthrax lethal factor.
    Lewis JA; Mongan J; McCammon JA; Cohen SM
    ChemMedChem; 2006 Jul; 1(7):694-7. PubMed ID: 16902919
    [No Abstract]   [Full Text] [Related]  

  • 11. The Pictet-Spengler reaction in solid-phase combinatorial chemistry.
    Nielsen TE; Diness F; Meldal M
    Curr Opin Drug Discov Devel; 2003 Nov; 6(6):801-14. PubMed ID: 14758752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.
    Karginov VA; Yohannes A; Robinson TM; Fahmi NE; Alibek K; Hecht SM
    Bioorg Med Chem; 2006 Jan; 14(1):33-40. PubMed ID: 16169738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
    Xiong Y; Wiltsie J; Woods A; Guo J; Pivnichny JV; Tang W; Bansal A; Cummings RT; Cunningham BR; Friedlander AM; Douglas CM; Salowe SP; Zaller DM; Scolnick EM; Schmatz DM; Bartizal K; Hermes JD; MacCoss M; Chapman KT
    Bioorg Med Chem Lett; 2006 Feb; 16(4):964-8. PubMed ID: 16338135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of polyvalent inhibitors of controlled molecular weight: structure-activity relationship for inhibitors of anthrax toxin.
    Gujraty KV; Joshi A; Saraph A; Poon V; Mogridge J; Kane RS
    Biomacromolecules; 2006 Jul; 7(7):2082-5. PubMed ID: 16827573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhodanine derivatives as selective protease inhibitors against bacterial toxins.
    Johnson SL; Chen LH; Harbach R; Sabet M; Savinov A; Cotton NJ; Strongin A; Guiney D; Pellecchia M
    Chem Biol Drug Des; 2008 Feb; 71(2):131-9. PubMed ID: 18221310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combating the threat of anthrax: a quantitative structure-activity relationship approach.
    Verma RP; Hansch C
    Mol Pharm; 2008; 5(5):745-59. PubMed ID: 18611038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-throughput screening approach to anthrax lethal factor inhibition.
    Johnson SL; Chen LH; Pellecchia M
    Bioorg Chem; 2007 Aug; 35(4):306-12. PubMed ID: 17320146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo.
    Pini A; Runci Y; Falciani C; Lelli B; Brunetti J; Pileri S; Fabbrini M; Lozzi L; Ricci C; Bernini A; Tonello F; Dal Molin F; Neri P; Niccolai N; Bracci L
    Biochem J; 2006 Apr; 395(1):157-63. PubMed ID: 16398644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of peptide-based anthrax toxin inhibitors.
    Gujraty K; Sadacharan S; Frost M; Poon V; Kane RS; Mogridge J
    Mol Pharm; 2005; 2(5):367-72. PubMed ID: 16196489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified strategy for Pictet-Spengler reaction leading to the synthesis of imidazoquinoxalines on solid phase.
    Kundu B; Sawant D; Chhabra R
    J Comb Chem; 2005; 7(2):317-21. PubMed ID: 15762762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.